|
Unomedical hereby submits this initial report as part of its complaint remediation activities conducted under a capa 2356421 and capa 2566479 in accordance with the fda action plan, which incorporates qp-ic-2026-0020 (ic retrospective complaint review) and qp-ic-2026-0024 (ic retrospective mdr review).This submission includes a retrospective reassessment of previously evaluated complaints.Unomedical is providing this supplemental information in accordance with the reporting requirements set forth in 21 cfr part 803.Any fields left blank indicate that the information is unknown, unavailable, or remains unchanged.Additional information - this medical device report (mdr) is being submitted to include the below: h6: investigation results under type of investigation, investigation findings, investigation conclusions.H11: investigation summary; complaint investigation results: a complaint investigation was performed based on the event description and no malfunction based on complaint information.Additional information was requested to support the investigation; however, a lot number or any product specific information was not provided.No device, device components, or other visual or physical evidence was made available for evaluation.Consequently, visual inspection, retain-sample testing, or the assessment of potential product performance issues, component integrity, or manufacturing defects could not be performed.In response to the complaint and due to the absence of a specific lot number, a high-level review of manufacturing controls for the minimed mio product family was conducted to document the routine controls used to detect potential defects at the product family level.The review identified the following controls in use for the minimed mio product family, including: 100% leak and flow testing during final assembly 100% visual inspections during packaging, verifying needle condition, tyvek seal integrity, contamination-free condition, and correct assembly.Sampling verification under acceptable quality limit (aql) 0.65, including visual and functional tests such as: burst test peel test flow and leak tests static tension test visual inspections for cannula, tubing, lid, heat-shrink and assembly integrity.Corrective and preventive action (capa) determination: based on the investigation, no further action is required.The record will be closed and monitored through tracking and trending per work instruction (wi) (monthly trips and alerts).Complaint investigation - conclusion: based on the limited information available, the investigation was completed and no product malfunction was alleged or identified.The complaint could not be confirmed due to insufficient information, and the record is being closed based on the event description and the information provided in the complaint.Based on the available information, this event is deemed to be a reportable death.To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 8021545 manufacturing site: 8021545.
|